Skip to content

Caspian Therapeutics

Total raised

$50.0M

+$50.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $50.0M
ROUNDS
1
INVESTORS
43
FOUNDED
2026
HQ
San Diego, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
N/A

AI overview

Updated

Caspian Therapeutics is a San Diego biotech spun out of Kura Oncology in September 2026 to develop small-molecule menin inhibitors as potentially disease-modifying therapies for diabetes and cardiometabolic diseases. Its lead compound, KO-7246, is a highly selective menin inhibitor designed for chronic metabolic use that aims to restore endogenous insulin production by expanding and improving the function of pancreatic beta cells. The company launched with a $50 million financing led by BVF Partners to take KO-7246 through IND-enabling work and initial clinical proof-of-concept.

What sets it apart

Builds on more than a decade of Kura Oncology's menin-inhibition R&D; aims to modify diabetes by restoring beta-cell function rather than only managing blood glucose.

Funding history

1 round
EquitySep 8, 2026
Form D
+$50.0M$50.0M total

Latest SEC filings

via EDGAR · CIK 0002156247
Form D · Sep 8, 2026NewView on EDGAR

Products

1 tracked

KO-7246

Small-molecule drug candidate (preclinical)

Next-generation, highly selective small-molecule menin inhibitor optimized for chronic metabolic disease; in preclinical models it selectively expanded pancreatic beta cells, increased insulin production and improved glycemic control in Type 1 and Type 2 diabetes models.

  • Highly selective menin inhibition
  • Preclinical beta-cell expansion and increased insulin production
  • Durable glycemic improvements persisting after treatment stopped in preclinical models
  • Phase 1 trial expected to begin by end of 2027, with data in 2028

Links

WebsiteSEC EDGAR filings